Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis |
| |
Authors: | C-C?Chiu C-H?M?Y?Lin Email author" target="_blank">K?FangEmail author |
| |
Institution: | (1) Department of Biological Science, National Taiwan Normal University, Taipei, Taiwan;(2) Department of Biological Science, National Taiwan Normal University, Taipei, Taiwan |
| |
Abstract: | Human non-small-cell-lung-cancer (NSCLC) cells of p53-null genotype were exposed to low-dosage topoisomearse II inhibitor etoposide (VP-16). The cellular proliferation rate could be effectively inhibited by VP-16 in dose-dependent manner. The effective drug concentration for growth inhibition could be as low as 0.5 M and the apoptotic phenotype became evident 48 h later. In H1299 cells, VP-16-induced cytotoxic effect was demonstrated associated with apoptosis that disappeared when restored with wild-type p53. Cell cycle analysis revealed that, upon VP-16 induction, cell death began with growth arrest by accumulating cells at the G2-M phase. The cells at sub-G1 phase increased at the expense of those at G2-M transition state. To assess the regulation of cell cycle modulators, western blot analysis of H1299 cell lysates showed the release of apoptosis initiator, cytochrome c and apaf-1 hours following drug induction. The cleavage of downstream effectors, procaspase-9 and procaspase-7, but not procaspase-3, was accompanied with proteolysis of poly-(ADP-ribose) polymerase (PARP). VP-16-activated procaspase-7 cleavage was abrogated in cells with ectopically expressed p53.On the other hand, the inhibited procaspase-7 fragmentation by caspase-specific inhibitor reversed apoptotic phenotype caused by drug induction. Thus, VP-16-induced apoptotic cell death was contributed by caspase-7 activation inp53-deficient human NSCLC cells. |
| |
Keywords: | etoposide VP-16 human non-small-cell-lung-cancer cells cell cycle and apoptosis |
本文献已被 PubMed SpringerLink 等数据库收录! |
|